Frontline treatment of multiple myeloma in elderly patients
- 1 November 2008
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 22 (6) , 303-309
- https://doi.org/10.1016/j.blre.2008.04.002
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Multiple myelomaBlood, 2008
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyBlood, 2006
- Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaCancer, 2005
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialBlood, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma PatientsBlood, 1999
- Multiple MyelomaNew England Journal of Medicine, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969